By Robert Preidt
HealthDay Reporter

MONDAY, Aug. 2, 2021 (HealthDay Information) — May a drug used to deal with amyotrophic lateral sclerosis (ALS) assist individuals with delicate Alzheimer’s disease?

The outcomes of a small new research counsel the technique might work.

Riluzole has been used for greater than 20 years to sluggish the development of ALS, generally known as Lou Gehrig’s illness. This section 2 research discovered that the drug slowed mind metabolic decline and had a optimistic impact on cognition in individuals with delicate Alzheimer’s.

It included 50 sufferers ages 50 to 90 who obtained both the drug (26) or a placebo (24) twice each day for six months.

“Utilizing two varieties of brain scans as biomarkers — this research was in a position to measure enhancements in mind metabolism amongst handled sufferers and correlate these enhancements with cognitive modifications and illness development,” stated research co-author Dr. Howard Fillit, founding government director and chief science officer of the Alzheimer’s Drug Discovery Basis.

“It’s a repurposed drug, which helps pace the analysis course of. It targets an essential and understudied organic mechanism that goes awry with getting older, and the rigorous design of this trial measured each biomarker and medical outcomes,” Fillit famous in a basis information launch.

Riluzole targets a neurotransmitter within the mind known as glutamate, which performs an important position within the means of nerve cells to ship indicators to 1 one other. Glutamate dysregulation is believed to start out a cycle of toxicity concerned in Alzheimer’s illness, the researchers stated.

The research discovered vital modifications in glutamate ranges in sufferers who obtained the drug. Charges of opposed occasions had been the identical amongst sufferers who took riluzole and those that took the placebo.

The outcomes had been lately printed on-line within the journal Brain.

These findings help a section 3 trial with bigger numbers of sufferers adopted for an extended time frame to additional assess the security and efficacy of the drug in Alzheimer’s sufferers, stated lead investigator Dr. Ana Pereira, assistant professor of neurology and neuroscience on the Icahn Faculty of Medication at Mount Sinai in New York Metropolis.

Extra info

The Alzheimer’s Affiliation has extra on Alzheimer’s disease.

SOURCE: Alzheimer’s Drug Discovery Basis, information launch, July 28, 2021